Günter Fingerle‐Rowson

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

Jürgen Bernhagen, Regina M. Krohn, Hongqi Lue et al. · Nature Medicine · 2007 · 1.3K citations

Life Sciences, Immunology, Molecular Biology +16

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

Robert A. Mitchell, Hong Liao, Jason Chesney et al. · Proceedings of the National Academy of Sciences · 2001 · 602 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka et al. · Blood · 2014 · 507 citations

Medicine, Genetics, Oncology +17